Innoveren Scientific Inc.
IVRN
$0.0002
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -100.00% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -100.00% | -- |
| Cost of Revenue | -- | -- | -- | -99.34% | -- |
| Gross Profit | -- | -- | -- | -100.58% | -- |
| SG&A Expenses | -30.91% | -52.64% | -61.16% | 1.84% | -60.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -30.91% | -54.24% | -64.03% | -13.87% | -63.86% |
| Operating Income | 30.91% | 50.11% | 46.76% | -29.21% | 50.31% |
| Income Before Tax | 78.25% | 131.13% | 46.29% | -99.88% | -288.58% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 78.25% | 131.13% | 46.29% | -99.88% | -288.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 78.25% | 131.13% | 46.29% | -99.88% | -288.58% |
| EBIT | 30.91% | 50.11% | 46.76% | -29.21% | 50.31% |
| EBITDA | 30.72% | 50.13% | 46.75% | -28.94% | 50.64% |
| EPS Basic | 90.96% | 110.86% | 85.32% | 18.62% | -95.14% |
| Normalized Basic EPS | 79.46% | 60.51% | 95.99% | 61.80% | 59.62% |
| EPS Diluted | 90.96% | 106.43% | 85.32% | 18.62% | -95.14% |
| Normalized Diluted EPS | 79.46% | 76.71% | 95.99% | 61.80% | 59.62% |
| Average Basic Shares Outstanding | 140.55% | 186.65% | 265.78% | 145.67% | 99.16% |
| Average Diluted Shares Outstanding | 140.55% | 385.88% | 265.78% | 145.67% | 99.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |